Cost-effectiveness results.
| Strategy | Cost | QALY | ICER (compared to monotherapy) | Incremental Analysis* | Net Benefit (£20,000) | Net Benefit Rank |
|---|---|---|---|---|---|---|
| Monotherapy | £55,996 | 13.73 | — | Dominated | £218,604 | 3 |
| Step-up | £50,791 | 11.91 | £2852 | Dominated | £187,409 | 5 |
| Parallel | £55,573 | 13.42 | £1356 | Dominated | £212,827 | 4 |
| Intensive | £61,046 | 15.77 | £2482 | £27,392 | £254,354 | 2 |
| Step-down | £48,849 | 15.32 | Cost saving Reference | strategy | £257,551 | 1 |
| Steroid | £57,468 | 11.79 | Dominated | Dominated | £178,332 | 6 |
↵* Incremental comparisons are against the next best, nondominated treatment strategy. QALY: quality-adjusted life-years; ICER: incremental cost-effectiveness ratios.